Gilead Sciences, Inc. (GILD) Faces its Greatest Threat to its Hepatitis C Drug: How Will That Impact Earnings? by Estimize
Gilead Sciences, Inc. (GILD) Healthcare – Biotechnology | Reports February 2, After Market Closes.
In August, Mohnish Pabrai took part in Brown University's Value Investing Speaker Series, answering a series of questions from students. Q3 2021 hedge fund letters, conferences and more One of the topics he covered was the issue of finding cheap equities, a process the value investor has plenty of experience with. Cheap Stocks In the Read More
- This quarter the Estimize consensus is more bullish than Wall Street, calling for EPS of $3.06 and revenue of $8.18 billion
- Gilead’s recent string of success can be attributed to the strength of its antiviral portfolio
- Merck recently launched a cheaper Hepatitis C drug which will put pressure Gilead’s margins and sales.
- What are you expecting for GILD? Get your estimate in here!